{
    "clinical_study": {
        "@rank": "70378", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Single ascending oral doses in fasted conditions"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Single ascending oral doses in fasted conditions"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "Single ascending oral doses in fed conditions"
            }
        ], 
        "brief_summary": {
            "textblock": "The study is designed to test safety tolerability and PK of single oral ascending doses of\n      PF-06305591,"
        }, 
        "brief_title": "Study to Investigate the Safety, Tolerability, Pharmacokinetics of PF-06305591 in Healthy Male and Female Subjects", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  healthy young subjects\n\n          -  aged 18-55\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or\n             allergic disease (including drug allergies, but excluding untreated, asymptomatic,\n             seasonal allergies at the time of dosing).\n\n          -  Pregnant or nursing females; females of childbearing potential."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01747941", 
            "org_study_id": "B5281001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cohort 1", 
                "description": "single dose, solution", 
                "intervention_name": "PF-06305591", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 1", 
                "description": "matching placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "description": "single dose, solution", 
                "intervention_name": "PF-06305591", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "description": "matching placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "description": "single dose, solution", 
                "intervention_name": "PF-06305591", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "description": "matching placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 22, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5281001&StudyName=Study%20to%20Investigate%20the%20Safety%2C%20Tolerability%2C%20Pharmacokinetics%20of%20PF-06305591%20in%20Healthy%20Male%20and%20Female%20Subjects%20"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Brussels", 
                    "country": "Belgium", 
                    "zip": "B-1070"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Double Blind (3rd Party Open) Randomized, Placebo Controlled, Crossover Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics of PF-06305591 in Healthy Male and Female Subjects", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium : Commission d'Ethique Biom\u00e9dicale Hospitalo-Facultaire", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)", 
            "safety_issue": "No", 
            "time_frame": "72 hr"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01747941"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]", 
            "safety_issue": "No", 
            "time_frame": "72 hr"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}